Semaglutide

Technology

Last mentioned: Mar 25, 2026

Timeline

  1. Black Market Surge

    Current reports highlight the critical risk of black market drugs due to the blurring of medicine and cosmetics.

  2. Regulatory Pivot

    Regulators begin targeting social media platforms for 'cosmetic' marketing of prescription drugs.

  3. Counterfeit Warning

    The WHO issues a global alert regarding falsified semaglutide products found in legitimate supply chains.

  4. Global Shortages Begin

    Novo Nordisk and Eli Lilly report significant supply constraints for semaglutide and tirzepatide.

Stories mentioning Semaglutide 1

About Semaglutide coverage

This page surfaces every story mentioning Semaglutide across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Semaglutide was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.